Human iPSC with Insulin Differentiation Reporter (GFP)
Quick Actions
Documentation 1 files
Product Overview
Description
The IPSCD001 cell line is a Human Induced Pluripotent stem cell (iPSC) line engineered with a knock-in GFP reporter under the control of the endogenous insulin (INS) gene promoter. This line enables real-time visualization and quantification of pancreatic ?-cell differentiation. Upon differentiation towards pancreatic lineage, GFP expression is activated specifically in insulin-producing cells.
-Genetic modification: INS-2A-GFP knock-in at the INS locus (homozygous or heterozygous .
- Parental cell line: Human dermal fibroblast-derived iPSC (confirmed trilineage differentiation capacity).
- Reporter sensitivity: Detected as early as the immature ?-cell stage (day 20–25 of differentiation).
IMPORTANT: Quality warranty requires use of NeoBioPharma media. Biohazardous material despite negative pathogen testing. Quality claims must be reported within 1 month.
Key Features
Catalog Number: IPSCD001
Product Format: Frozen
Vial Cell Number: > 5x10[5] cells/vial
Passage:1(P1)
Storage: Liquid Nitrogen, Vapor Phase
Intended Use: Research use only (RUO)
Quick Facts
Product Type
Stem Cells
Viability
>90% viable (Trypan Blue exclusion)
Applications
Research & Development
Availability
In Stock • Global Shipping
Technical Specifications
Applications & Use Cases
Research Areas
In Vitro Studies
Cell culture and screening applications
Molecular Biology
Gene expression & signaling studies
Drug Discovery
Screening & validation studies
Disease Modeling
Pathophysiology research
Support & Resources
Technical Support
Our experts are available for technical questions and protocol assistance.
Contact Support
